Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
6.33
-0.53 (-7.73%)
At close: Nov 20, 2026, 4:00 PM EST
6.39
+0.06 (0.95%)
After-hours: Nov 20, 2026, 7:30 PM EST
Verastem Revenue
Verastem had revenue of $24.01M in the quarter ending September 30, 2026, with 113.59% growth. This brings the company's total for the last twelve months to $100.30M, up 649.65% year-over-year. In the year 2025, Verastem had annual revenue of $30.91M with 209.14% growth. That makes Verastem the 22,696th largest company in the world by revenue and 3,285th in the United States.
Revenue (ttm)
$100.30M
Revenue Growth
+649.65%
P/S Ratio
7.95
Revenue / Employee
$983,294
Employees
102
Market Cap
797.67M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.91M | 20.91M | 209.14% |
| Dec 31, 2024 | 10.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
| Dec 31, 2018 | 26.72M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 386.75M |
| Syndax Pharmaceuticals | 289.68M |
| Immatics | 49.33M |
| City Therapeutics | 14.34M |
| Aktis Oncology | 12.39M |
| Inventiva | 2.81M |
| Odyssey Therapeutics | 99.00K |
VSTM News
- 2 days ago - Verastem Oncology Announces Late-Breaking Oral Presentation of VS-7375 Lung Cancer Data at IASLC/ASCO 2026 North America Conference on Lung Cancer - Business Wire
- 4 days ago - Verastem Transcript: Jefferies Global Healthcare Conference - Transcripts
- 10 days ago - Verastem Transcript: 8th Annual Wolfe Research Healthcare Conference - Transcripts
- 11 days ago - Verastem Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 15 days ago - Verastem price target raised to $20 from $18 at H.C. Wainwright - TheFly
- 15 days ago - Verastem files automatic mixed securities shelf - TheFly
- 15 days ago - Verastem Earnings Call Transcript: Q3 2026 - Transcripts
- 15 days ago - Verastem Quarterly report: Q3 2026 - Filings